Hematology

Fabio Ciceri

 

Hematology and Bone Marrow Transplantation Unit Transfusion Medicine

PROFESSIONAL RECORD

  • Head, Bone Marrow Transplantation Unit, Dept. of Hematology and Bone Marrow Transplantation, San Raffaele Scientific Institute ,2001 – October 2005
  • Director, Hematology and Bone Marrow Transplantation Unit, Dept. of Oncology, San Raffaele Scientific Institute, October 2005 – present
  • Director, Blood Transfusion Service – June 2012 – present
  • Associate Professor of Hematology, University Vita-Salute San Raffaele – July 2015-present
  • Director, Post-Graduate School of Hematology, University Vita-Salute San Raffaele. Nov 2015-present
  • International cooperation: Coordination of international cooperation programs:  professional training and activation of BMT Unit at Tishreen Hopital, Damascus Syria (http://www.fondazioneime.com/news.aspx?ln=it&id=16&n=7); implementing  hemato-oncology activity in Lacor Hospital, Gulu Uganda (http://www.lhospital.org); professional training and activation of hemato-oncology activity in Oncologic Hospital of Tachira, San Cristobal Venezuela (http://www.ftmovenezuela.org).

Fabio Ciceri studied Medicine at the University of Pavia; he was awarded a Merit Recognition Award while a medical student and during his residency in Clinical Immunology and Rheumatology at the University of Ferrara. From 1989 to 1995, he was attending physician at the Department of Internal Medicine of San Raffaele Scientific Institute as Postdoctoral Research Fellow involved in cancer immunotherapy programs.
Fabio Ciceri joined the Hematology and Bone Marrow Transplantation Unit in 1995 and obtained National Board  of Hematology in 2001. Since 2005 he is Director of Hematology and BMT Unit at San Raffaele Scientific Institute. Since 2008 he is Associate Director, Division of Research of Regenerative Medicine, Cell and Gene Therapy at  San Raffaele Scientific Institute.
Fabio Ciceri has over 50 publications in peer-reviewed journals (including key research papers in Nature Medicine, the Lancet Oncology, New England Journal of Medicine and Blood). He has been invited to lecture and chair at more than 50 national and international meetings.

CLINICAL FACILITIES
Hematology and BMT is a 36 beds- Unit dedicated to comprehensive and intensive care of hematology and BMT.
Focus of Hematology and BT Unit is the cure and clinical research in all malignant and non-malignant blood diseases. The unit runs Cell and Gene Therapy clinical trials for hematological cancers, immune-deficiencies, neuromuscolar disorder.
The Unit is developing transplantation from partially HLA-incompatible (haploidentical) family members to offer a cure to all patients affected by high-risk hematologic malignancies who are candidate to allogeneic Hematopoietic Stem Cell Transplantation. Over the last years, we developed both T-cell depleted and T-cell replete platforms for haploSCT. Extensive application of T-cell depletion is limited by high rate of late transplant related mortality (TRM) and relapse associated with the inadequate immune reconstitution (IR) due to ex vivo T cell depletion or in vivo post-transplant cyclophosphamide administrationfor severe graft-vs-host disease (GvHD) prevention. We extensively developed HSV-TK+ suicide gene donor lymphocytes after haploidentical transplantation (haplo-HSCT). A phase III trial (TK008, NCT00914628) is ongoing in 8 centres in Europeand US and preliminary results confirm safety and potential benefit in improving survival of the T-cell gene transfer technology integrated with T-cell depleted HaploSCT. We developed unmanipulated peripheral blood stem cells haploSCT by exploring a calcineurin inhibitor- free rapamycin-based GvHD prophylaxis. regimen (TrRaMM study, Eudract 2007-5477-54). We showed that rapamycin allowed the preferential expansion of donor-derived natural T regulatory cell (Tregs), ultimately protecting from the severe GvHD that would have been expected in this context. Building on this promising experience, we are currently testing several new rapamycin-based regimens to improve the efficacy and feasibility of haploidentical HSCT. In more than fifty patients with high-risk malignancies we combined a treosulfan- and fludarabinebased chemotherapeutic regimen to low-dose Total Body Irradiation (4Gy TBI) modulating in vivo T cell depletion with ATG-Fresenius on the basis of donor-recipient matching and underlying disease risk (TrRaMM4Gy study, Eudract 2011-001534-42). Specific effort is dedicated to the biological characterization of immune reconstitution, comprising the detailed analysis of the early and late immune events.

IMMUNOHEMATOLOGY AND TRANSFUSION MEDICINE UNIT
The Hospital San Raffaele (OSR) Immunohematology and Transfusion Medicine Service (ITMS) provides clinical services to support OSR patients in need of blood component therapy, cellular therapy, therapeutic apheresis, and specialized laboratory diagnostics. This ISO 9002 Certified unit collects and prepares the blood components and cellular therapy products used in patient care at the OSR, maintain an accredited Immunohematology Reference Lab and provides education in the field of Transfusion Medicine. ITMS is conducting a project, funded by Regione Lombardia, on the appropriateness of blood transfusion.
The ITMS is subdivided into two distinct subunits, each responsible for a particular process:

BLOOD DONATION CENTER
The blood donation center subunit is responsible for the collection and testing of blood to be transfused into patients at the San Raffaele Hospital. It is responsible for handling all aspects of donor recruitment for whole blood products, apheresis products, the auto-transfusion program and therapeutic phlebotomy. During 2013 were presented to make a donation 8424 candidates of these only 6820 have donated. 5535 were donations of whole blood and the rest were donations by apheresis, plateletpheresis or plasmapheresis.

THERAPEUTIC APHERESIS AND CELLULAR THERAPY
The Therapeutic Apheresis and Cellular Therapy subunit is responsible for collecting and processing hematopoietic stem cells and performs the necessary diagnostic testing required for bone marrow transplantation procedures. The lab supplies hematopoietic stem cells and relevant cells in support of clinical trials for allogenic bone marrow and peripheral blood transplantation and offers a Stem Cell Cryo Banking service for autologous and allogeneic bone marrow products. Bone Marrow from qualified donors is collected in accordance and recognition of the Italian Bone Marrow Donor Registry (IBMDR). Therapeutic apheresis procedures to treat patients with neurologic and blood diseases, including photopheresis, red cell and plasma exchange procedures are also performed routinely.
The unit of therapeutic apheresis is part of the bone marrow transplants program and underwent Jacie Accreditation Inspection in October 2013.
During 2014, were performed 212 apheresis for the collection HSCT.

REFERENCES

  • Total publications: 183
  • 2014 Total publications: 31
  • h index (Scopus): 35
  • Citations (Scopus): 3097
  • Mean citations: 21.8
  • Impact factor (IF) total: 1041
  • Mean IF: 8,3.

MEDICAL CONFERENCES

  • Promoters of > 10/year
  • Prof Ciceri is invited Speaker in 80 national and 120 international conferences since 2004.

EQUIPE (ALL HEMATOLOGISTS)

  • Carrabba Matteo
  • Guggiari Elena
  • Lunghi Francesca
  • Lupo Stanghellini Maria Teresa
  • Morelli Mara
  • Giglio Fabio
  • Mastaglio Sara
  • Messina Carlo
  • Greco Raffaella
  • Piemontese Simona
  • Vago Luca
  • Gentner Bernhard
  • Bondanza Attilio
  • Dalto Serena.

Paolo Prospero Ghia

 

WORK EXPERIENCE
From January 2016 – Today
Università Vita – Salute San Raffaele, Medical School, Via Olgettina 58, 20132, Milano, Italia and Dipartimento di Oncoematologia, Ospedale San Raffaele, via Olgettina, 60, 20132 – Milano, Italy

Associate professor in Internal Medicine
Main activities and responsibilities:

  • Director, Strategic Research Program on Chronic Lymphocytic Leukemia
  • Deputy Director, Division of experimental Oncology, San Raffaele Scientific Institute, Milano
  • Head, Laboratory of B Cell Neoplasia, Division of Experimental Oncology
  • Teaching appointment in Internal Medicine and Medical Oncology
  • Clinical care of patients affected by Chronic Lymphocytic Leukemia and related disorders
  • Principal Investigator/National coordinator in international clinical trials in CLL and related disorders.

From March 2010 – December 2015
Università Vita – Salute San Raffaele, Medical School, Via Olgettina 58, 20132, Milano, Italia and Dipartimento di Oncoematologia, Ospedale San Raffaele, via Olgettina, 60, 20132 – Milano, Italy
Associate professor in Internal Medicine
Main activities and responsibilities:

  • Scientific Coordinator, Unit of Lymphoid Malignancies
  • Deputy Director, Division of Molecular Oncology, San Raffaele Scientific Institute, Milano
  • Head, Laboratory of B Cell Neoplasia, Division of Molecular Oncology
  • Teaching appointment in Internal Medicine and Molecular Oncology
  • Clinical care of patients affected by Lymphoproliferative disorders
  • Principal Investigator/National coordinator in international clinical trials in CLL and indolent lymphomas.

From January 2005 – February 2010
Università Vita – Salute San Raffaele, Medical School, Via Olgettina 58, 20132, Milano, Italia
Assistant professor in Internal Medicine
Main activities and responsibilities:

  • Head, Laboratory of B Cell Neoplasia (2009), Division of Molecular Oncology
  • Scientific Coordinator, Unit of Lymphoid Malignancies (2008), Department of Onco-Hematology
  • Teaching appointment in Internal Medicine and Molecular Oncology
  • Clinical care of patients affected by Lymphoproliferative disorders.

From 1998 - 2004
Università degli Studi di Torino, Facoltà di Medicina e Chirurgia, Via Verdi 15, 10126, Torino, Italia
Assistant professor in Internal Medicine
Main activities and responsibilities:

  • Head, Unit of Tumor Immunology, Institute for Cancer Research and Treatment, Candiolo, Torino, Italy (2003-2004)
  • Teaching appointment in Medicine and Biotechnology
  • Clinical care of hematological in- and out-patients.

From 1996 - 1998
Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney street, 02115, Boston (MA), USA
Research Associate
Main activities and responsibilities:

  • Research activity, Division of hematologic Malignancies, Dana-Farber Cancer Institute Supervision of undergraduate and PhD students.

From 1993 - 1996
Basel Institute for Immunology, 487 Grenzacherstrasse, Basel, Switzerland
Scientific Member
Main activities and responsibilities:

  • Basic Research in human Immunology.

EDUCATION AND TRAINING
From 1998 - 2003

Università degli Studi di Torino, II Medical School, Orbassano (TO), Italia
Internal Medicine Residency, Medical Internist

From 1991 - 1994
Università degli Studi di Torino, Medical School, Torino, Italia
PhD Course in Human Oncology, PhD degree

From 1984 - 1990
Università degli Studi di Torino, Medical School, Torino, Italia
Medicine, Medical Doctor degree

SOCIAL SKILLS AND COMPETENCES

  • Prolonged experience abroad in multicultural settings and great skills in working together with other people in both academic research environment and clinical activities for in- and out-patients care, where teamwork is essential. Prolonged experience in the management of patients affected by neoplastic disorders, in particular of the hematologic type in daily clinical activity as well as in the context of experimental clinical trials.

ORGANISATIONAL SKILLS AND COMPETENCES

  • Professional experience in leading and conducting national and international randomized clinical trials; great skills in obtaining and administering Research budgets from private and public funding sources; great capacity in elaborating and conducting research projects at international level; solid experience in coordination and administration of highly motivated people with elevated professional background, as medical residents, physicians, PhD students, post-doctoral fellows. Course in Good Clinical Practice for clinical trials.

TECHNICAL SKILLS AND COMPETENCES

  • Clinical management of patients affected by Lymphoproliferative disorders. Principal Investigators in National and International Clinical Trials for CLL and indolent Lymphomas
  • Member of National and International Advisory Boards of Pharma industries. Handling and interpretation of innovative technique in molecular medicine, oncology and biology.

OTHER SKILLS AND COMPETENCES

  • President, European Research Initiative on CLL (ERIC) (2015- 2017)
  • Member: WHO Clinical Advisory Committee for Lymphocytic and Histiocytic Malignancies (2014-2016)
  • Associate editor (CLL and related disorders) for Haematologica/The Hematology Journal (2014-2017)
  • Section Editor (CLL and related disorders) for Leukemia Journal (2008-2013);
  • Deputy Editor (Lymphoma and CLL) for Blood Cancer Journal (2010-2014);
  • Reviewer for peer-reviewed journals, including Blood, Leukemia, Haematologica, Leukemia Research, Leukemia & Lymphoma.
  • Member: Steering committee of the European Research Initiative on CLL (ERIC), www.ericll.org
  • Member of the Organizing and Scientific Committee of the “Educational Workshop of Immunoglobulin Genes analysis in Chronic Lymphocytic Leukemia” (Uppsala, 2007; Parigi, 2008; Salonicco 2009; Stresa 2011, Brno 2013), www.igcll.com
  • Co-organizer, II and III edition, “Young CLL Investigators Meeting” (London 2007; Cologne 2008)
  • Member of the Technical and Scientific Committee of the Italian Association for Cancer Research (AIRC) (2008-2013)
  • Member: Scientific Program Committee (SPC) (CLL and Lymphoma expert) of the European Hematology Association (EHA) (2007-2011)
  • Member of National and International Scientific Societies: American Society of Hematology (ASH), American Association of Immunologists (AAI), European Hematology Association (EHA), American Association for Cancer Research (AACR) Henry Kunkel Society of America, Rockefeller University, New York, Società Italiana di Ematologia Sperimentale (SIES), Società Italiana di Immunologia, Immunologia Clinica e Allergologia (SIICA).

Publications in Extenso (Selected from 2011)